Keros Therapeutics Inc (NAS:KROS)
$ 55.04 -0.58 (-1.04%) Market Cap: 2.07 Bil Enterprise Value: 1.70 Bil PE Ratio: 0 PB Ratio: 4.73 GF Score: 39/100

Keros Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 07:40PM GMT
Release Date Price: $39.84 (+2.23%)
Unidentified Participant

Great. Good afternoon. I just have to read this disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. So, I'm very pleased to introduce the CEO of Keros, Jas Seehra, and nice to see you Jas.

Jasbir Seehra
Keros Therapeutics, Inc. - CEO

Thanks. Very pleased to be here today.

Unidentified Participant

Great. Before we dive into granular questions, perhaps you can just provide a little bit of an overview on Keros and also your focus in the TGF beta superfamily.

Jasbir Seehra
Keros Therapeutics, Inc. - CEO

Keros is a clinical-stage biopharmaceutical company focused entirely on the TGF-beta superfamily and inhibiting the signaling pathways of TGF-beta. We have three product candidates that are in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot